136 related articles for article (PubMed ID: 31467231)
1. Mts1 Up-regulation is Associated With Aggressive Pathological Features in Thyroid Cancer.
Cheon MG; Son YW; Lee JH; Jang HH; Chung YS
Cancer Genomics Proteomics; 2019; 16(5):369-376. PubMed ID: 31467231
[TBL] [Abstract][Full Text] [Related]
2. The role of Slit2 as a tumor suppressor in thyroid cancer.
Jeon MJ; Lim S; You MH; Park Y; Song DE; Sim S; Kim TY; Shong YK; Kim WB; Kim WG
Mol Cell Endocrinol; 2019 Mar; 483():87-96. PubMed ID: 30648543
[TBL] [Abstract][Full Text] [Related]
3. IGF-IEc Expression Is Associated With Advanced Differentiated Thyroid Cancer.
Karagiannis AK; Philippou A; Tseleni-Balafouta S; Zevolis E; Nakouti T; Tsopanomichalou-Gklotsou M; Psarras V; Koutsilieris M
Anticancer Res; 2019 Jun; 39(6):2811-2819. PubMed ID: 31177118
[TBL] [Abstract][Full Text] [Related]
4. High expression and localization of β-catenin and epidermal growth factor receptor identify high risk papillary thyroid carcinoma patients.
Išić Denčić T; Bartolome A; Šelemetjev S; Đorić I; Tatić S; Živaljević V; Cvejić D
Exp Mol Pathol; 2018 Oct; 105(2):181-189. PubMed ID: 30077672
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-1266 suppresses papillary thyroid carcinoma cell metastasis and growth via targeting FGFR2.
Fu YT; Zheng HB; Zhang DQ; Zhou L; Sun H
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3430-3438. PubMed ID: 29917195
[TBL] [Abstract][Full Text] [Related]
6. Long Noncoding RNA HOXA-AS2 Promotes Papillary Thyroid Cancer Progression by Regulating miR-520c-3p/S100A4 Pathway.
Xia F; Chen Y; Jiang B; Du X; Peng Y; Wang W; Huang W; Feng T; Li X
Cell Physiol Biochem; 2018; 50(5):1659-1672. PubMed ID: 30384358
[TBL] [Abstract][Full Text] [Related]
7. RANKL, OPG, TRAIL, KRas, and c-Fos expression in relation to central lymph node metastases in papillary thyroid carcinoma.
Deligiorgi MV; Mahaira H; Eftychiadis C; Kafiri G; Georgiou G; Theodoropoulos G; Konstadoulakis MM; Zografos E; Zografos GC
J BUON; 2018; 23(4):1029-1040. PubMed ID: 30358208
[TBL] [Abstract][Full Text] [Related]
8. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression.
Huang Y; Yu S; Cao S; Yin Y; Hong S; Guan H; Li Y; Xiao H
Thyroid; 2018 Sep; 28(9):1162-1173. PubMed ID: 29882471
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling identifies potential molecular markers of papillary thyroid carcinoma.
Reyes I; Reyes N; Suriano R; Iacob C; Suslina N; Policastro A; Moscatello A; Schantz S; Tiwari RK; Geliebter J
Cancer Biomark; 2019; 24(1):71-83. PubMed ID: 30614796
[TBL] [Abstract][Full Text] [Related]
11. Proteomics study of serum exosomes from papillary thyroid cancer patients.
Luo D; Zhan S; Xia W; Huang L; Ge W; Wang T
Endocr Relat Cancer; 2018 Oct; 25(10):879-891. PubMed ID: 29895528
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for skip metastasis and lateral lymph node metastasis of papillary thyroid cancer.
Zhao H; Huang T; Li H
Surgery; 2019 Jul; 166(1):55-60. PubMed ID: 30876667
[TBL] [Abstract][Full Text] [Related]
13. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
14. An Evaluation of Clinicopathological Factors Effective in the Development of Central and Lateral Lymph Node Metastasis in Papillary Thyroid Cancer.
Aydin Buyruk B; Kebapci N; Yorulmaz G; Buyruk A; Kebapci M
J Natl Med Assoc; 2018 Aug; 110(4):384-390. PubMed ID: 30126565
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma.
Shen L; Qian C; Cao H; Wang Z; Luo T; Liang C
World J Surg Oncol; 2018 Dec; 16(1):235. PubMed ID: 30558624
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
17. Lymph node metastasis-dependent molecular classification in papillary thyroid carcinoma defines aggressive metastatic outgrowth.
Seo DH; Lee SG; Lee HY; Jeong S; Park S; Lee J; Jo YS
Clin Transl Med; 2023 Mar; 13(3):e1211. PubMed ID: 36929616
[No Abstract] [Full Text] [Related]
18. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of lipid metabolism-related gene expression-based molecular subtype in papillary thyroid cancer.
Xu M; Sun T; Wen S; Zhang T; Wang X; Cao Y; Wang Y; Sun X; Ji Q; Shi R; Qu N
Acta Biochim Biophys Sin (Shanghai); 2020 Oct; 52(10):1166-1170. PubMed ID: 32880619
[No Abstract] [Full Text] [Related]
[Next] [New Search]
